BioAtla Investor Presentation Deck

Phase 2 study design with BA3011 (Mecbotamab Vedotin) in refractory NSCLC patients Initial interim analysis AXL+ ≥1 TmPS Monotherapy and Combination with PD-1/L1 All patients refractory to PD-1/L1, EGFR and / or ALK inhibitors Targeting up to ~20 pts bicatla Next step If definitive, move into part 2 Ability to continue interim enrollment up to ~40 patients, if desired Phase 2 part 2 Monotherapy (BA3011) and / or Combination (BA3011+Opdivo) n=TBD pending discussions with FDA Endpoints Primary endpoints Confirmed ORR per RECIST v1.1 AES or SAEs Secondary endpoints DOR, PFS, ORR, DCR, TTR, OS BA3011 dose 1.8 mg/kg Q2W. Inclusion criteria: measurable disease, ≥ 18 years, ECOG performance status 0 or 1. AE, adverse event; BOR, best overall response; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SAE, serious adverse event; TTR, time to response. BioAtla| Overview 17

View entire presentation